Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $30
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $22 to $30.
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $22 to $30.